Compare GSK plc (GSK) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Rockwell Automation — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Rockwell Automation trades at $432.38 (market cap $48.21B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Rockwell Automation for 74 Days on average.
| GSK | ROK | |
|---|---|---|
Market Cap | $91.88B | $48.21B |
Volume | 7,730,529 | 953,342 |
Sector | Health | Industrials |
52-Week High | $61.18 | $495.08 |
52-Week Low | $43.24 | $333.75 |
Typical Hold Time | 93 Days | 74 Days |
Enterprise Value | $111.88B | $51.34B |
Dividend Yield | 3.9% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Rockwell Automation (ROK) trades at $432.59, down 2.11% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 49.09% gross margin and 34.47% ROE, though net income declined to $869M in 2025. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and robotic platforms, supporting positive long-term demand trends.
The stock presents a mixed outlook: analyst consensus targets $489.89 (13% upside) with a majority Hold rating, but high valuation ratios (P/E 40.65) and recent earnings misses pose risks. Key opportunities include automation tailwinds from data centers and labor shortages, while execution on revenue growth and margin stabilization remains critical for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
